

KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Center and Hospital Limited) Coimbatore, Tamil Nadu

Department Of Pharmacology

New Drug Update

(New Drugs and Available Drugs with New Formulation)



Series - 9 April 2020

In this series

New drugs approved by FDA

- 1. Isatuximab-irfc
- 2. Bimatoprost Implant
- 3. Osilodrostat
- 4. Ozanimod

COMPILED & EDITED by

Department of Pharmacology KMCHIHSR, Coimbatore.

Kindly Mail Your Suggestions To: hodpharmacology@kmchihsr.edu.in

Access this series through website: www.kmchihsr.edu.in

1.Isatuximab-irfc

Date of Approval: March 2, 2020 Mechanism of action: CD38-directed cytolytic antibody Indication: Multiple Myeloma in combination with Pomalidomide and Dexamethasone Dosage Formulation: IV Infusion

2.Bimatoprost Implant

Date of Approval: March 3, 2020 Mechanism of action: PG-F2a analogue, reduces IOP Indication: Open Angle Glaucoma Dosage Formulation: Intra-cameral, Biodegradable Sustained-Release Implant

<u>3.Osilodrostat</u> (Received Orphan Drug Designation) Date of Approval: March 6, 2020 Mechanism of action: Cortisol synthesis inhibitor Indication: Adults with Cushing's Syndrome who cannot undergo pituitary gland surgery or have undergone surgery

Dosage Formulation: Tablet

4. Ozanimod

Date of Approval: March 25, 2020 Mechanism of action: Sphingosine 1-phosphate receptor modulator Indication: Relapsing Multiple Sclerosis Dosage Formulation: Capsule